Synlogic Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Airbnb, Y-mAbs Therapeutics, Neuronetics
U.S. STOCKS ON THE MOVE-Boeing, TScan Therapeutic, Under Armour
U.S. STOCKS ON THE MOVE-Alto Ingredients, Squarespace, Palantir
U.S. STOCKS ON THE MOVE-ClearOne, Coty, Novavax
Synlogic rises on FDA's 'orphan drug' tag for blood disorder treatment
Brief: Synlogic Receives Orphan Drug Designation From FDA For Synb1934 For Treatment Of Phenylketonuria
Synlogic Inc expected to post a loss of 23 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in December - Earnings Summary
Brief: Synlogic Reports Fourth Quarter 2022 Results
Synlogic Inc expected to post a loss of 25 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Walt Disney, Personalis, Netflix
U.S. STOCKS ON THE MOVE- NextDecade, Eli Lilly, Norwegian
U.S. STOCKS ON THE MOVE-Apple, Surmodics, Domino's
Brief: Synlogic Receives Rare Pediatric Disease Designation From FDA For Synb1934
Synlogic rises on 'rare pediatric disease' tag for blood disorder treatment
Brief: Synlogic Provides Corporate Update And Outlook For 2023
Brief: Synlogic Announces Achievement Of Proof Of Concept For Synb8802 On Urinary Oxalate Lowering In Phase 1B Study
Brief: Synlogic Inc - On Dec 6, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing